((-)-1-(3-hydroxypropyl)-5-((2R)-2-{[2-({2-[(2,2,2-trifluoroethyl)oxy]phenyl} oxy)ethyl]amino}propyl)-2,3-dihydro-1H-indole-7-carboxamide), an =1A-adrenoceptor antagonist with potency similar to that of tamsulosin, is under development for the treatment of bladder outlet obstruction in patients with benign prostatic hypertrophy. In the present study, we investigated the effects of KMD-3213 on the tilt-induced blood pressure response in anesthetized normotensive rats. Male normotensive SpragueDawley rats were placed in the supine position on a board under cocktail anesthetization (a-chloralose, urethane and sodium pentobarbital). The arterial blood pressure was measured from the carotid artery. The animals were given consistent 45° head-up tilt from the horizontal position, following the transient decrease in the blood pressure, and then recovery of the blood pressure to the normal level. Significant orthostatic hypotension was seen with intravenous administration of both prazosin and tamsulosin at doses over 3 mg /kg, and these drugs completely blocked the tilt-induced blood pressure responses at 30 mg/kg. On the other hand, these responses were still retained when KMD-3213 was administered intravenously at a dose up to 75 mg/kg of KMD-3213. Moreover, KMD-3213 showed the highest uroselectivity of the test drugs. These results indicate that KMD-3213 is not likely to induce orthostatic hypotension and would be a useful compound for the treatment of urinary outlet obstruction in patients with benign prostatic hyperplasia.
Orthostatic (or postural) hypotension is defined as an excessive fall in blood pressure in assuming an upright position. The gravitational stress of standing causes blood to pool in the venous capacitance vessels on the legs, with a subsequent transient decrease in venous return, cardiac output, and blood pressure. In general, baroreceptors in the arch of the aorta and carotid glomus trigger the normal sympathetic nerve reflex in order to recover the normal blood pressure. However, some kind of drugs, such as sympathetic nerve blockers and vasodilators often cause the orthostatic hypotension. This complication may seriously reduce the clinical usefulness of these drugs. Therefore, it is essential that drugs having a novel mechanism of action with a vascular effect should be tested for its orthostatic effects in preclinical studies (1) .
In recent years, a 1-adrenoceptor (AR) antagonists have been the first choice for the pharmacotherapy of the bladder outlet obstruction (BOO) seen in patients with benign prostatic hyperplasia (BPH) in order to reduce urethral resistance. However, these drugs, including prazosin, terazosin and doxazosin, frequently induce orthostatic hypotension as an adverse event, which is due to a reduction in the peripheral arterial resistance mediated by a blockade of vascular = 1 -ARs. Therefore, it is highly desirable to develop an a1-AR antagonist that can selectively suppress the tone of the lower urinary tract without having vascular effects for the treatment of BOO in patients with BPH. Currently, the a1-AR is classified into three cloned subtypes: a 1a, a1b and a 1d and three native subtypes: a1A, a1B and a 1D (2) . There are a number of reports indicating that the a 1a-AR subtype is the predominant a1-AR subtype in the human prostate (3 -5) . Moreover, the contractile response of human prostate to norepinephrine is mediated by the a 1A-AR (6), while a 1B-AR is predominant in human peripheral arteries and aorta (7, 8) . These findings suggest a possibility for the development of an a 1A -AR antagonist specific for the prostate. Moreover, tamsulosin HCl (Harnal in Japan), which has relatively higher selectivity for this subtype, was reported to have higher uroselectivity than the first generation a 1-AR antagonists, including prazosin (9, 10) . Thus, a 1A -AR subtype selectivity of a 1 -AR antagonists has received a great deal of attention.
KMD-3213 is a novel a 1A-AR-selective antagonist (11, 12) , which is under development for the treatment of BOO in patients with BPH. We have demonstrated that KMD-3213, a new a1A-AR antagonist, shows substantial uroselectivity in both in vitro and in vivo experiments (12 -14) . Moreover, KMD-3213 potently inhibited noradrenaline-induced contraction of isolated human prostate with a similar potency similar to that of tamsulosin (8, 15) . These data suggest a therapeutic usefulness of KMD-3213 for the treatment of urinary outlet obstruction in patients with BPH.
Since some of the cardiovascular side effects associated with a 1-AR antagonist therapy of BPH are exacerbated upon standing, it is appropriate to evaluate uroselectivity in animal models of orthostatic hypotension. In the present study, we determined the ability of KMD-3213 to block urethral and vascular a 1-ARs in the rat and compared the urethral blocking doses with those required to influence the blood pressure response to tilt in this species. This comparison may provide another index to predict the usefulness of urogenital a 1 -AR antagonists in patients with BPH to reduce urethral resistance without affecting the vascular response on assuming an erect posture.
MATERIALS AND METHODS

General procedure for experiments
This study was conducted according to the guidelines approved by the Experimental Animal Ethics Committee of KISSEI Pharmaceutical Co., Ltd.
Male normotensive Sprague-Dawley rats (Japan SLC Inc., Shizuoka), 9 -11 weeks old and weighing 250 -350 g, were treated with intravenous administration of a cocktail of anesthetics of the following composition: achloralose (40 mg /kg), urethane (40 mg /kg), and pentobarbital (15 mg /kg) in a volume of 10 mL /kg of 5% glucose. This anesthetization was well established by Stephen et al. (16) for the estimation of the effects of certain compounds on the tilt-induced blood pressure response. Then, the rats were fixed in the supine position on a stainless mesh board. The left common carotid artery was cannulated with polyethylene tube (PE-50; Becton and Dickinson, Franklin Lakes, NJ, USA) in order to monitor the systemic arterial pressure with a pressure transducer (DX-312; Nihon Kohden, Tokyo) placed at the heart level so that the tilting would not influence artificially the arterial blood pressure. Observation of the tilt-induced blood pressure response was performed as follows: rats were suddenly subjected to a consistent 45° head-up tilt from the horizontal position with the aid of a shaft that was placed at the heart level to serve as a fulcrum. Each tilt was timed to last 120 s. The load of tilt was performed repeatedly until the stable blood pressure response was obtained. When the normal blood pressure response (Fig. 1,  control) was not observed before the test drugs were administered, these rats were omitted from the study.
Data analyses
Mean blood pressure (MBP) was taken immediately before tilt (at 0 s) and at 5, 10, 20, 30, 60 and 120 s after the start of tilt. Changes in the MBP from the baseline value before the tilt (D MBP) were plotted against time after the start of tilt. Then, we calculated AUC0 -120 (area under the curve of the change in DMBP) value. AUC 0 -120 values obtained at 3 or 10 min after the drug administration were compared with that value before drug administration by the paired t-test. The 5% level of the difference was considered significant.
In order to estimate the uroselectivity of the test compounds, we compared the ED15 value (dose at which a test compound decreased by 15% the difference in the DMBP value between the control and 3 min after the drug administration at 30 s after tilt) with the ID50 value (dose at which a test compound inhibited the phenylephrine-induced increase in the urethral pressure response by 50%, which were values that we reported earlier (14) . Uroselectivity was defined as the ratio of ED 15 to ID 50 .
Compounds and solutions
KMD-3213
dihyrobromide and tamsulosin hydrochloride were synthesized in the chemical section of our laboratory. Prazosin hydrochloride was purchased from Sigma (St. Louis, MO, USA). All other chemicals were of reagent grade.
In the present study, the dihyrobromide salt of KMD-3213 was dissolved and diluted in Hartmann's solution of the following composition (W /V%): NaCl, 0.60; KCl, 0.03; CaCl 2 , 0.02; lactic acid, 0.31 (lactate-Ringer solution). Absolute doses of KMD-3213 were converted into the salt-free KMD-3213 for the data analysis. Tamsulosin was dissolved in physiological saline and diluted with the same solution to the appropriate concentrations. Prazosin was dissolved in distilled water and diluted with physiological saline to the appropriate concentrations.
RESULTS
At first, we found that combined use of a-chloralose and pentobarbital and urethane gave good anesthetization that did not suppress the tilt response (control tilt responses in Fig. 1 ). We tried to use pentobarbital or urethane as anesthetics individually. However, the single use of these anesthetics made it difficult to reproduce the response; i.e., the response disappeared (data not shown). Some rats treated with mixture of three anesthetics did not show the complete tilt response. These rats were not adopted to the experiments. Therefore, test compounds were only administered to the rats that exhibited the complete control tilt response. Table 1 shows the basal MBP obtained just before tilt and at 3 min and 10 min after the administration of KMD-3213, tamsulosin or prazosin. All three compounds decreased the MBP in a dose-dependent manner. Significant reductions were observed at 1 mg/kg, i.v. of tamsulosin and prazosin; however, 23 m g/kg, i.v. or greater was required for significant reduction in the case of KMD-3213.
Representative recordings of the blood pressure response to tilt before and after administration of the compounds (KMD-3213: 23 mg/kg, tamsulosin and prazosin: 3 m g/kg) are shown in Fig. 1 . All groups exhibited complete MBP compensation in the control (before drug administration) after a transient drop in the blood pressure. Three minutes after the administration of the drugs, as compared with the compensation with 23 mg/kg, i.v. of KMD-3213, 3 mg/kg, i.v. of tamsulosin or prazosin apparently depressed the tiltinduced blood pressure response. Figure 2 shows the changes in MBP during 45° head up tilt for 120 s before and 3 min and 10 min after the administration of various doses of KMD-3213, tamsulosin and prazosin. Tamsulosin and prazosin at more than 3 -10 mg/kg, i.v. completely depressed the tilt-induced blood pressure response. Although, 230 mg/kg, i.v. of KMD-3213 completely depressed the response, partial compensation was observed up to 75 mg /kg, i.v. of KMD-3213.
AUC 0 -120 values (area under the DMBP curve during 120-s tilt) are indicated in Table 2 . Significant increases in the AUC0 -120 values were observed at more than 23 mg /kg, i.v. of KMD-3213. However, tamsulosin and prazosin increased the value starting from 3 mg/kg, i.v. AUC0 -120 values determined at 10 min after drug administration did not seem to be different from the values obtained at 3 min after the drug administration in each case.
In order to estimate the uroselectivity of the test com- pounds, we compared the dose-response to the orthostatic hypotensive effects with the inhibition of the phenylephrine-induced increase in urethral pressure that we had already reported (14) . As shown in Fig. 3 , KMD-3213 depressed the phenylephrine-induced increase in the urethral pressure response at doses substantially lower than those required to inhibit the tilt-induced blood pressure response; that is, KMD-3213 showed greater uroselectivity. Prazosin reduced blood pressure and urethral responses at equivalent doses, whereas tamsulosin showed a modest uroselectivity. The ED15 and ID50 values of test compounds, which are evaluations of the potency in inducing orthostatic hypotension and inhibiting the phenylephrine-induced urethral pressure response, respectively, are shown in the Table 3 . As we have already reported (14) , the rank order of potency of the inhibition of phenylephrine-induced increase in the urethral pressure was tamsulosin > KMD-3213 > prazosin. On the other hand, the rank order of potency of inhibition of the tilt-induced blood pressure response was tamsulosin > prazosin > KMD-3213. Thus, the uroselectivity index of KMD-3213, 57, was much higher than that of tamsulosin or prazosin (4.0 or 1.1, respectively). 
DISCUSSION
Prazosin, one of first-generation drugs of the a 1 -AR antagonist type for the treatment of BOO in patients with BPH, must be administered with dose titration because of its "first dose phenomenon". Such drugs often cause orthostatic hypotension at a similar dose for the treatment of BOO at the beginning of the dosing.
Second-generation drugs, such as tamsulosin, were developed in order to suppress the occurrence of hypotension by increasing prostate selectivity. Tamsulosin has relatively higher affinity for the a 1A -AR and a 1D -AR than for the a 1B-AR (17) . In the case of tamsulosin, however, it was reported that the conventional preparation caused hypotension in the phase I study (18) . It was probably derived by "the first dose phenomenon" and "the Cmax effect", which is the occurrence of side effects around the Cmax at the time after administration of the drug. After that, tamsulosin, which had succeeded as a delayed release preparation (19) without dose titration, was reported neither to reduce basal blood pressure nor to produce orthostatic hypotension (20 -23) .
We developed KMD-3213, an a1A-AR-super selective antagonist, as a third-generation a 1-AR antagonist for the treatment of BOO in patients with BPH. KMD-3213 has higher affinity for the human a 1A -AR, but several hundredfold and 50-fold lower affinity for the a 1B-and a 1D-ARs, respectively (11, 12) . Furthermore, many preclinical studies revealed that KMD-3213 has higher uroselectivity (prostate selectivity) than tamsulosin (13, 14, 24 -27) .
As described above, since, a 1-AR antagonist therapy often causes orthostatic hypotension, we estimated the effect of KMD-3213 on the tilt-induced blood pressure response in the anesthetized rat. In this model, blood pressure transiently decreases just after the 45° head-up tilt, but quickly recovers by a compensatory reflex. After 3 to 10 mg/kg of tamsulosin and prazosin given intravenously, the tilt-induced blood pressure responses were significantly depressed, whereas more than 23 m g/kg of KMD-3213 was required for significant suppression of these responses (Table 2) . Moreover, KMD-3213 had the highest uroselectivity index (Table 3) . These results agree very well with the several data that we reported (14, 26) . On the other hand, significant reductions in the basal MBP were observed at 1 and 3 mg/kg, i.v. of tamsulosin and prazosin, respectively. However, 23 mg/kg or greater was required for the significant reduction in the case of KMD-3213 (Table 1) .
According to these results, we propose that drugs having little potency to decrease the basal MBP, would not induce orthostatic hypotension. Furthermore, drugs that have a higher a 1A -AR subtype selectivity would unlikely induce orthostatic hypotension. Recently, Take et al. (28) reported that naftopidil, which has a relatively higher affinity for the a 1D -AR subtype than for the a 1A -and a 1B -ARs, did not cause orthostatic hypotension compared with prazosin. In the results of Take et al., the drug, which has a 1B-AR-low affinity, does not cause orthostatic hypotension and may have good tolerability in clinical use. However, tamsulosin induced significant orthostatic hypotension with similar potency to prazosin in the present study, although the affinity for the a1B-AR subtype of this compound was 1 /10 lower than that of prazosin (11, 12) . This discrepancy is still debatable. As a1-AR subtypes have species-derived differences in their pharmacological properties and tissue distribution, it would be complicated to directly extrapolate our results obtained in rats to humans. In any event, the hypothesis that KMD-3213 has low affinity for the receptor that controls the vascular system could be true in the present rat model.
In conclusion, intravenously administered KMD-3213 exhibited excellent uroselectivity in comparison with tamsulosin and prazosin in this model. This finding is of clinical advantage; i.e., KMD-3213 would be useful for the treatment of BOO in patients with BPH, without inducing orthostatic hypotension. ED15: dose at which the test compound decreased by 15% the difference in the D MAP at 30 s after tilt between the before and 3 min after the administration of the compound. ID50: dose at which the test compound inhibited the phenylephrine-induced increase in urethral pressure response by 50%. Data are taken from the literature (14) .
